Tumour angiogenesis articles within Nature Medicine

Featured

  • Article |

    Factors secreted by metastatic a primary tumors induce an early phenotypic switch in perivascular cells at distant pre-metastatic niches. By using sophisticated lineage-tracing mouse models, the authors demonstrate that enhanced KLF4 expression in these cells increases their ability to proliferate and migrate away from the vasculature, and augments fibronectin deposition, which contributes to metastatic growth. These findings increase the mechanistic understanding of the metastatic process and uncover a role for perivascular plasticity that could be targeted to prevent metastasis.

    • Meera Murgai
    • , Wei Ju
    •  & Rosandra N Kaplan

  • News & Views |

    A recent study confirms an association between vessel co-option and resistance to bevacizumab, an anti-vascular endothelial growth factor-A (VEGFA) antibody, in patients with liver metastases. The authors suggest a combined therapeutic strategy that reduces co-option in mice.

    • Kyrre E Emblem
    •  & Rakesh K Jain

  • Article |

    Poor responses of liver metastases to the anti-angiogenic agent bevacizumab in patients with colorectal and breast cancer correlate with tumor co-option of pre-existing blood vessels, a mechanism of tumor resistance that might be targeted by the inhibition of cancer cell motility.

    • Sophia Frentzas
    • , Eve Simoneau
    •  & Andrew R Reynolds

  • News & Views |

    Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy (pages 1114–1123).

    • Eleni Maniati
    •  & Thorsten Hagemann

  • Article |

    The cytokine PDGF has multiple effects on the vasculature and influences tumor growth and progression. Yuan Xue et al. uncover a new role for PDGF as a regulator of hematopoiesis and provide a unifying mechanism by which PDGF induction of the cytokine erythropoietin in stromal cells underlies PDGF's effects on both hematopoiesis and the tumor vasculature.

    • Yuan Xue
    • , Sharon Lim
    •  & Yihai Cao

  • Technical Report |

    Tony Ko and his colleagues introduce a fluorescence microendoscopy imaging approach for time-lapse studies of deep brain tissue previously inaccessible to conventional optical imaging techniques. It can be used to study the cellular effects of brain disease over weeks to months with comparable resolution to light microscopy. They use the approach to monitor individual hippocampal neurons, neuronal dendrites and blood vessels and to follow the process of glioma angiogenesis.

    • Robert P J Barretto
    • , Tony H Ko
    •  & Mark J Schnitzer

  • News & Views |

    The angiogenic switch, which leads to the activation of endothelial cell proliferation and the growth of new blood vessels, is a crucial step in tumorigenesis. A study now shows that this process is linked to a microRNA in endothelial cells (909–914). Blocking microRNAs may offer new avenues for antiangiogenesis therapy to treat cancer.

    • Hanna M Eilken
    •  & Ralf H Adams

  • Letter |

    Sudarshan Anand et al. show that endothelial cell expression of the microRNA miR-132 targets a negative regulator of Ras pathway signaling and thereby releases a brake to new blood vessel formation. miR-132 expression is upregulated in the endothelium of human hemangioma and tumor samples, and an antagonist of miR-132, delivered specifically to tumor endothelium using an integrin-targeted nanoparticle, was able to inhibit tumor angiogenesis and growth in mice.

    • Sudarshan Anand
    • , Bharat K Majeti
    •  & David A Cheresh

Browse broader subjects

Browse Tumour angiogenesis across other nature.com journals